Skip to main content
ABBOTT LABORATORIES logo

ABBOTT LABORATORIES — Investor Relations & Filings

Ticker · ABT ISIN · US0028241000 LEI · HQD377W2YR662HK5JX27 US Manufacturing
Open in API
Filings indexed 4,256 across all filing types
Latest filing 2016-10-18 M&A Activity
Country US United States of America
Listing US ABT

About ABBOTT LABORATORIES

https://www.abbott.com

Abbott Laboratories is a global healthcare company that discovers, develops, manufactures, and sells a broad portfolio of life-changing technologies. The company's operations are focused on four core businesses: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. The Medical Devices division offers solutions for cardiovascular health, diabetes care (including the FreeStyle Libre continuous glucose monitoring system), and neuromodulation. The Diagnostics segment provides a wide range of in vitro diagnostic systems and tests for hospitals, laboratories, and clinics. The Nutrition business develops and markets science-based nutritional products for people of all ages, with leading brands such as Similac, PediaSure, Ensure, and Glucerna. The Established Pharmaceuticals division provides a portfolio of branded generic medicines to consumers in emerging markets.

Recent filings

Filing Released Lang Actions
Abbott Laboratories Files Rule 425 Document
M&A Activity Classification · 95% confidence The document is a Rule 425 filing under the Securities Act of 1933 and Rule 14a-12 under the Securities Exchange Act of 1934, which is used for communications related to mergers and acquisitions. It announces the sale of certain business units from Abbott and St. Jude Medical to Terumo Corporation as part of Abbott's acquisition of St. Jude Medical. The document includes forward-looking statements, references to proxy statements and registration statements filed with the SEC, and details about the transaction and participants in the solicitation of proxies. It is not a full merger proxy statement or tender offer filing but a communication related to the merger process. This type of document fits best under the category of Merger & Acquisition (MA) filings, which include merger communications such as Form 425 filings. The document is 9474 characters long, contains substantive information about the transaction, and is not merely an announcement of a report or a certification. Therefore, the correct classification is MA with high confidence.
2016-10-18 English
FORM 4 -
Director's Dealing
2016-10-04 English
FORM 4 -
Director's Dealing
2016-10-04 English
FORM 4 -
Director's Dealing
2016-10-04 English
FORM 4 -
Director's Dealing
2016-10-04 English
FORM 4 -
Director's Dealing
2016-09-28 English

Browse filings by year

33 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.